Skip to main content
Erschienen in: International Journal of Hematology 6/2020

12.03.2020 | Original Article

Comparison of clinical phenotype with genetic and laboratory results in 31 patients with congenital dysfibrinogenemia in northern Slovakia

verfasst von: Tomas Simurda, Jana Zolkova, Zuzana Kolkova, Dusan Loderer, Miroslava Dobrotova, Ingrid Skornova, Monika Brunclíkova, Marian Grendar, Zora Lasabova, Jan Stasko, Peter Kubisz

Erschienen in: International Journal of Hematology | Ausgabe 6/2020

Einloggen, um Zugang zu erhalten

Abstract

Congenital dysfibrinogenemia (CD) is a rare disorder of hemostasis. The majority of cases are caused by heterozygous missense mutations in one of the three fibrinogen genes. Patients with CD may experience bleeding and thrombosis, but many are asymptomatic. To better describe the clinical, laboratory, and genotypic picture of CD, we evaluated 31 patients from seven unrelated families using standard coagulation tests and genetic analysis. The clinical phenotype consisted of bleeding in 13/31 (42%) patients; other patients (18/31; 58%) were asymptomatic. Among patients with bleeding, symptoms were mostly in single anatomical sites, with variable intensity of bleeding. Compared to results from a previous large systematic survey, our results showed a similar mean bleeding score, but a higher incidence of bleeding episodes without thrombotic complications. In the present study, we identified three known pathogenic point mutations in the FGA (c.95G > A, c.104G > A) and FGB (c.586C > T) genes. The variants of CD identified in this cross-sectional study were either asymptomatic or had bleeding manifestations and showed similar laboratory features, irrespective of genotype. Results from genetic and clinical studies will continue to yield valuable information on the structure and function of the fibrinogen molecule.
Literatur
1.
Zurück zum Zitat Simurda T, Snahnicanova Z, Loderer D, Sokol J, Stasko J, Lasbova Z, et al. fibrinogen martin: a novel mutation in FGB (GLN180STOP) causing congenital afibrinogenemia. Semin Thromb Hemost. 2016;42:455–8.PubMedCrossRef Simurda T, Snahnicanova Z, Loderer D, Sokol J, Stasko J, Lasbova Z, et al. fibrinogen martin: a novel mutation in FGB (GLN180STOP) causing congenital afibrinogenemia. Semin Thromb Hemost. 2016;42:455–8.PubMedCrossRef
2.
Zurück zum Zitat Asselta R, Platè M, Robusto M, Borhany M, Guella I, Soldà G, et al. Clinical and molecular characterisation of 21 patients affected by quantitative fibrinogen deficiency. Thromb Haemost. 2015;113:567–76.PubMedCrossRef Asselta R, Platè M, Robusto M, Borhany M, Guella I, Soldà G, et al. Clinical and molecular characterisation of 21 patients affected by quantitative fibrinogen deficiency. Thromb Haemost. 2015;113:567–76.PubMedCrossRef
3.
Zurück zum Zitat de Moerloose P, Casini A, Neerman-Arbez M. Congenital fibrinogen disorders: an update. Semin Thromb Hemost. 2013;39:585–95.PubMedCrossRef de Moerloose P, Casini A, Neerman-Arbez M. Congenital fibrinogen disorders: an update. Semin Thromb Hemost. 2013;39:585–95.PubMedCrossRef
4.
Zurück zum Zitat Cieśla M, Adamczyk Z, Barbasz J, Wasilewska M. Mechanisms of fibrinogen adsorption at solid substrates at lower pH. Langmuir. 2013;11(29):7005–166.CrossRef Cieśla M, Adamczyk Z, Barbasz J, Wasilewska M. Mechanisms of fibrinogen adsorption at solid substrates at lower pH. Langmuir. 2013;11(29):7005–166.CrossRef
5.
Zurück zum Zitat Platé M, Asselta R, Peyvandi F, Tenchini ML, Duga S. Molecular characterization of the first missense mutation in the fibrinogen Aalpha-chain gene identified in a compound heterozygous afibrinogenemic patient. Biochim Biophys Acta. 2007;1772:781–7.PubMedCrossRef Platé M, Asselta R, Peyvandi F, Tenchini ML, Duga S. Molecular characterization of the first missense mutation in the fibrinogen Aalpha-chain gene identified in a compound heterozygous afibrinogenemic patient. Biochim Biophys Acta. 2007;1772:781–7.PubMedCrossRef
6.
Zurück zum Zitat Casini A, Blondon M, Tintillier V, Goodyer M, Sezgin ME, Gunes AM, et al. Mutational epidemiology of congenital fibrinogen disorders. Thromb Haemost. 2018;118:1867–74.PubMedCrossRef Casini A, Blondon M, Tintillier V, Goodyer M, Sezgin ME, Gunes AM, et al. Mutational epidemiology of congenital fibrinogen disorders. Thromb Haemost. 2018;118:1867–74.PubMedCrossRef
7.
Zurück zum Zitat Simurda T, Zolkova J, Snahnicanova Z, Loderer D, Skornova I, Sokol J, et al. Identification of two novel fibrinogen Bβ chain mutations in two Slovak families with quantitative fibrinogen disorders. Int J Mol Sci. 2017;19:100.PubMedCentralCrossRef Simurda T, Zolkova J, Snahnicanova Z, Loderer D, Skornova I, Sokol J, et al. Identification of two novel fibrinogen Bβ chain mutations in two Slovak families with quantitative fibrinogen disorders. Int J Mol Sci. 2017;19:100.PubMedCentralCrossRef
8.
Zurück zum Zitat Zhou J, Zhu P, Zhang X. A Chinese family with congenital dysfibrinogenemia carries a heterozygous missense mutation in FGA: concerning the genetic abnormality and clinical treatment. Pak J Med Sci. 2017;33:968–72.PubMedPubMedCentral Zhou J, Zhu P, Zhang X. A Chinese family with congenital dysfibrinogenemia carries a heterozygous missense mutation in FGA: concerning the genetic abnormality and clinical treatment. Pak J Med Sci. 2017;33:968–72.PubMedPubMedCentral
9.
Zurück zum Zitat Blombäck M, Blombäck B, Mammen EF. Fibrinogen Detroit—a molecular defect in the N-terminal disulphide knot of human fibrinogen? Nature. 1968;218:134–7.PubMedCrossRef Blombäck M, Blombäck B, Mammen EF. Fibrinogen Detroit—a molecular defect in the N-terminal disulphide knot of human fibrinogen? Nature. 1968;218:134–7.PubMedCrossRef
10.
Zurück zum Zitat Miesbach W, Galanakis D, Scharrer I. Treatment of patients with dysfibrinogenemia and a history of abortions during pregnancy. Blood Coagul Fibrinolysis. 2009;20:366–70.PubMedCrossRef Miesbach W, Galanakis D, Scharrer I. Treatment of patients with dysfibrinogenemia and a history of abortions during pregnancy. Blood Coagul Fibrinolysis. 2009;20:366–70.PubMedCrossRef
11.
Zurück zum Zitat Simurda T, Dobrotova M, Skornova I, Zolkova J, Plamenova I, Ivankova J, et al. Congenital dysfibrinogenemia—laboratory diagnostics and treatment approaches. Vask Med. 2018;10:90–3. Simurda T, Dobrotova M, Skornova I, Zolkova J, Plamenova I, Ivankova J, et al. Congenital dysfibrinogenemia—laboratory diagnostics and treatment approaches. Vask Med. 2018;10:90–3.
12.
Zurück zum Zitat Simurda T, Kubisz P, Dobrotova M, Neca L, Stasko J. Perioperative coagulation management in a patient with congenital afibrinogenemia during revision total hip arthroplasty. Semin Thromb Hemost. 2016;42:689–92.PubMedCrossRef Simurda T, Kubisz P, Dobrotova M, Neca L, Stasko J. Perioperative coagulation management in a patient with congenital afibrinogenemia during revision total hip arthroplasty. Semin Thromb Hemost. 2016;42:689–92.PubMedCrossRef
13.
Zurück zum Zitat Casini A, Neerman-Arbez M, Ariëns RA, de Moerloose P. Dysfibrinogenemia: from molecular anomalies to clinical manifestations and management. J Thromb Haemost. 2015;13:909–19.PubMedCrossRef Casini A, Neerman-Arbez M, Ariëns RA, de Moerloose P. Dysfibrinogenemia: from molecular anomalies to clinical manifestations and management. J Thromb Haemost. 2015;13:909–19.PubMedCrossRef
14.
Zurück zum Zitat Luo M, Deng D, Xiang L, Cheng P, Liao L, Deng X, et al. Three cases of congenital dysfibrinogenemia in unrelated Chinese families: heterozygous missense mutation in fibrinogen alpha chain Argl6His. Medicine (Baltimore). 2016;95:4864.CrossRef Luo M, Deng D, Xiang L, Cheng P, Liao L, Deng X, et al. Three cases of congenital dysfibrinogenemia in unrelated Chinese families: heterozygous missense mutation in fibrinogen alpha chain Argl6His. Medicine (Baltimore). 2016;95:4864.CrossRef
15.
Zurück zum Zitat Rodeghiero F, Tosetto A, Abshire T, Arnold DM, Coller B, James P, et al. ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost. 2010;8:2063–5.PubMedCrossRef Rodeghiero F, Tosetto A, Abshire T, Arnold DM, Coller B, James P, et al. ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost. 2010;8:2063–5.PubMedCrossRef
16.
Zurück zum Zitat Hanss M, Biot F. A database for human fibrinogen variants. Ann N Y Acad Sci. 2001;936:89–90.PubMedCrossRef Hanss M, Biot F. A database for human fibrinogen variants. Ann N Y Acad Sci. 2001;936:89–90.PubMedCrossRef
18.
Zurück zum Zitat Shapiro SE. Diagnosis and management of dysfibrinogenemia. Clin Adv Hematol Oncol. 2018;16:602–5.PubMed Shapiro SE. Diagnosis and management of dysfibrinogenemia. Clin Adv Hematol Oncol. 2018;16:602–5.PubMed
20.
Zurück zum Zitat Miesbach W, Scharrer I, Henschen A, Neerman-Arbez M, Spitzer S, Galanakis D. Inherited dysfibrinogenemia: clinical phenotypes associated with five different fibrinogen structure defects. Blood Coagul Fibrinolysis. 2010;21:35–40.PubMedCrossRef Miesbach W, Scharrer I, Henschen A, Neerman-Arbez M, Spitzer S, Galanakis D. Inherited dysfibrinogenemia: clinical phenotypes associated with five different fibrinogen structure defects. Blood Coagul Fibrinolysis. 2010;21:35–40.PubMedCrossRef
21.
Zurück zum Zitat Casini A, Blondon M, Lebreton A, Koegel J, Tintillier V, de Maistre E, et al. Natural history of patients with congenital dysfibrinogenemia. Blood. 2015;125:553–61.PubMedPubMedCentralCrossRef Casini A, Blondon M, Lebreton A, Koegel J, Tintillier V, de Maistre E, et al. Natural history of patients with congenital dysfibrinogenemia. Blood. 2015;125:553–61.PubMedPubMedCentralCrossRef
22.
Zurück zum Zitat Shapiro SE, Phillips E, Manning RA, Morse CV, Murden SL, Laffan MA, et al. Clinical phenotype, laboratory features and genotype of 35 patients with heritable dysfibrinogenaemia. Br J Haematol. 2013;160:220–7.PubMedCrossRef Shapiro SE, Phillips E, Manning RA, Morse CV, Murden SL, Laffan MA, et al. Clinical phenotype, laboratory features and genotype of 35 patients with heritable dysfibrinogenaemia. Br J Haematol. 2013;160:220–7.PubMedCrossRef
23.
Zurück zum Zitat Haverkate F, Samama M. Familial dysfibrinogenemia and thrombophilia report on a study of the SSC subcommittee on fibrinogen. Thromb Haemost. 1995;73:151–61.PubMedCrossRef Haverkate F, Samama M. Familial dysfibrinogenemia and thrombophilia report on a study of the SSC subcommittee on fibrinogen. Thromb Haemost. 1995;73:151–61.PubMedCrossRef
24.
Zurück zum Zitat Casini A, de Moerloose P, Neerman-Arbez M. Clinical features and management of congenital fibrinogen deficiencies. Semin Thromb Hemost. 2016;42:366–74.PubMedCrossRef Casini A, de Moerloose P, Neerman-Arbez M. Clinical features and management of congenital fibrinogen deficiencies. Semin Thromb Hemost. 2016;42:366–74.PubMedCrossRef
25.
Zurück zum Zitat de Moerloose P, Boehlen F, Neerman-Arbez M. Fibrinogen and the risk of thrombosis. Semin Thromb Hemost. 2010;36:7–17.PubMedCrossRef de Moerloose P, Boehlen F, Neerman-Arbez M. Fibrinogen and the risk of thrombosis. Semin Thromb Hemost. 2010;36:7–17.PubMedCrossRef
27.
Zurück zum Zitat Lebreton A, Casini A. Diagnosis of congenital fibrinogen disorders. Ann Biol Clin (Paris). 2016;74:405–12. Lebreton A, Casini A. Diagnosis of congenital fibrinogen disorders. Ann Biol Clin (Paris). 2016;74:405–12.
28.
Zurück zum Zitat Miesbach W, Schenk J, Alesci S, Lindhoff-Last E. Comparison of the fibrinogen clauss assay and the fibrinogen PT derived method in patients with dysfibrinogenemia. Thromb Res. 2010;126:428–33.CrossRef Miesbach W, Schenk J, Alesci S, Lindhoff-Last E. Comparison of the fibrinogen clauss assay and the fibrinogen PT derived method in patients with dysfibrinogenemia. Thromb Res. 2010;126:428–33.CrossRef
29.
Zurück zum Zitat Neerman-Arbez M, de Moerloose P, Casini A. Laboratory and genetic investigation of mutations accounting for congenital fibrinogen disorders. Semin Thromb Hemost. 2016;42:356–65.PubMedCrossRef Neerman-Arbez M, de Moerloose P, Casini A. Laboratory and genetic investigation of mutations accounting for congenital fibrinogen disorders. Semin Thromb Hemost. 2016;42:356–65.PubMedCrossRef
30.
Zurück zum Zitat Lefkowitz JB, DeBoom T, Weller A, Clarke S, Lavrinets D. Fibrinogen Longmont: a dysfibrinogenemia that causes prolonged clot-based test results only when using an optical detection method. Am J Hematol. 2000;63:149–55.PubMedCrossRef Lefkowitz JB, DeBoom T, Weller A, Clarke S, Lavrinets D. Fibrinogen Longmont: a dysfibrinogenemia that causes prolonged clot-based test results only when using an optical detection method. Am J Hematol. 2000;63:149–55.PubMedCrossRef
31.
Zurück zum Zitat Casini A, Undas A, Palla R, et al. Diagnosis and classification of congenital fibrinogen disorders: communication from the SSC of the ISTH. J Thromb Haemost. 2018;1(6):1887–900.CrossRef Casini A, Undas A, Palla R, et al. Diagnosis and classification of congenital fibrinogen disorders: communication from the SSC of the ISTH. J Thromb Haemost. 2018;1(6):1887–900.CrossRef
32.
Zurück zum Zitat Paraboschi EM, Duga S, Asselta R. Fibrinogen as a pleiotropic protein causing human diseases: the mutational burden of Aα, Bβ, and γ chains. Int J Mol Sci. 2017;18:2711.PubMedCentralCrossRef Paraboschi EM, Duga S, Asselta R. Fibrinogen as a pleiotropic protein causing human diseases: the mutational burden of Aα, Bβ, and γ chains. Int J Mol Sci. 2017;18:2711.PubMedCentralCrossRef
33.
Zurück zum Zitat Asselta R, Robusto M, Platé M, Santoro C, Peyvandi F, Duga S. Molecular characterization of 7 patients affected by dys- or hypo-dysfibrinogenemia: identification of a novel mutation in the fibrinogen Bbeta chain causing a gain of glycosylation. Thromb Res. 2015;136:168–74.PubMedCrossRef Asselta R, Robusto M, Platé M, Santoro C, Peyvandi F, Duga S. Molecular characterization of 7 patients affected by dys- or hypo-dysfibrinogenemia: identification of a novel mutation in the fibrinogen Bbeta chain causing a gain of glycosylation. Thromb Res. 2015;136:168–74.PubMedCrossRef
34.
Zurück zum Zitat Tiscia GL, Margaglione M. Human fibrinogen: molecular and genetic aspects of congenital disorders. Int J Mol Sci. 2018;19:1597.PubMedCentralCrossRef Tiscia GL, Margaglione M. Human fibrinogen: molecular and genetic aspects of congenital disorders. Int J Mol Sci. 2018;19:1597.PubMedCentralCrossRef
35.
Zurück zum Zitat Batorova A, Jankovicova D, Lazur J, et al. Vrodena dysfibrinogenemia a hypofibrinogenemia—molekulova baza a klinicky fenotyp. Interna medicina. 2016;16:109–15. Batorova A, Jankovicova D, Lazur J, et al. Vrodena dysfibrinogenemia a hypofibrinogenemia—molekulova baza a klinicky fenotyp. Interna medicina. 2016;16:109–15.
37.
Zurück zum Zitat Kadir R, Chi C, Bolton-Maggs P. Pregnancy and rare bleeding disorders. Haemophilia. 2009;15:990–1005.PubMedCrossRef Kadir R, Chi C, Bolton-Maggs P. Pregnancy and rare bleeding disorders. Haemophilia. 2009;15:990–1005.PubMedCrossRef
38.
Zurück zum Zitat Kotlin R, Zichová K, Suttnar J, Reicheltová Z, Salaj P, Hrachovinová I, et al. Congenital dysfibrinogenemia Aα Gly13Glu associated with bleeding during pregnancy. Thromb Res. 2011;127:277–8.PubMedCrossRef Kotlin R, Zichová K, Suttnar J, Reicheltová Z, Salaj P, Hrachovinová I, et al. Congenital dysfibrinogenemia Aα Gly13Glu associated with bleeding during pregnancy. Thromb Res. 2011;127:277–8.PubMedCrossRef
39.
Zurück zum Zitat Gaja A, Terasawa F, Okumuna N. Hereditární dysfibrinogenemie s Aa13Gly%3eGlu mutací. In: Malý M, Pecka J, editors. Trombóza a hemostáza. HK Credit: Hradec Králové; 2001. p. 114. Gaja A, Terasawa F, Okumuna N. Hereditární dysfibrinogenemie s Aa13Gly%3eGlu mutací. In: Malý M, Pecka J, editors. Trombóza a hemostáza. HK Credit: Hradec Králové; 2001. p. 114.
40.
Zurück zum Zitat Asselta R, Duga S, Spena S, D'Angelo F, Casetta B, Papa ML, et al. Congenital afibrinogenemia: mutations leading to premature termination codons in fibrinogen Aα-chain gene are not associated with the decay of the mutant mRNAs. Blood. 2001;98:3685–92.PubMedCrossRef Asselta R, Duga S, Spena S, D'Angelo F, Casetta B, Papa ML, et al. Congenital afibrinogenemia: mutations leading to premature termination codons in fibrinogen Aα-chain gene are not associated with the decay of the mutant mRNAs. Blood. 2001;98:3685–92.PubMedCrossRef
41.
Zurück zum Zitat Yan J, Luo M, Cheng P, Liao L, Deng X, Deng D, et al. A novel mutation in the fibrinogen Aα chain (Gly13Arg, fibrinogen Nanning) causes congenital dysfibrinogenemia associated with defective peptide A release. Int J Hematol. 2017;105:506–14.PubMedCrossRef Yan J, Luo M, Cheng P, Liao L, Deng X, Deng D, et al. A novel mutation in the fibrinogen Aα chain (Gly13Arg, fibrinogen Nanning) causes congenital dysfibrinogenemia associated with defective peptide A release. Int J Hematol. 2017;105:506–14.PubMedCrossRef
42.
Zurück zum Zitat Mathonnet F, Peltier JY, Detruit H, de Raucourt E, Alvarez JC, Mazmanian GM, et al. Fibrinogen Saint-Germain I: a case of the heterozygous Aalpha GLY 12→ VAL fibrinogen variant. Blood Coagul Fibrinolysis. 2002;13:149–53.PubMedCrossRef Mathonnet F, Peltier JY, Detruit H, de Raucourt E, Alvarez JC, Mazmanian GM, et al. Fibrinogen Saint-Germain I: a case of the heterozygous Aalpha GLY 12→ VAL fibrinogen variant. Blood Coagul Fibrinolysis. 2002;13:149–53.PubMedCrossRef
43.
Zurück zum Zitat Lounes KC, Lefkowitz JB, Henschen-Edman AH, Coates AI, Hantgan RR, Lord ST. The impaired polymerization of fibrinogen Longmont (Bbeta166Arg→ Cys) is not improved by removal of disulfide-linked dimers from a mixture of dimers and cysteine-linked monomers. Blood. 2001;98:661–6.PubMedCrossRef Lounes KC, Lefkowitz JB, Henschen-Edman AH, Coates AI, Hantgan RR, Lord ST. The impaired polymerization of fibrinogen Longmont (Bbeta166Arg→ Cys) is not improved by removal of disulfide-linked dimers from a mixture of dimers and cysteine-linked monomers. Blood. 2001;98:661–6.PubMedCrossRef
44.
Zurück zum Zitat van Vulpen LFD, Amin SN, Makris M. Severe wound healing impairment in a patient with dysfibrinogenaemia. Thromb Haemost. 2018;118:430–2.PubMedCrossRef van Vulpen LFD, Amin SN, Makris M. Severe wound healing impairment in a patient with dysfibrinogenaemia. Thromb Haemost. 2018;118:430–2.PubMedCrossRef
45.
Zurück zum Zitat Liao Z, Tang H, Xie Y, Duan X, Xu S, Liu C, et al. Fibrinogen hangzhou: congenital dysfibrinogenemia caused by the novel missense mutation in FGG (γ308Asn→Thr). Clin Chim Acta. 2014;428:106–9.PubMedCrossRef Liao Z, Tang H, Xie Y, Duan X, Xu S, Liu C, et al. Fibrinogen hangzhou: congenital dysfibrinogenemia caused by the novel missense mutation in FGG (γ308Asn→Thr). Clin Chim Acta. 2014;428:106–9.PubMedCrossRef
46.
Zurück zum Zitat Santacroce R, Cappucci F, Pisanelli D, Perricone F, Papa ML, Santoro R, et al. Inherited abnormalities of fibrinogen: 10-year clinical experience of an Italian group. Blood Coagul Fibrinolysis. 2006;17:235–40.PubMedCrossRef Santacroce R, Cappucci F, Pisanelli D, Perricone F, Papa ML, Santoro R, et al. Inherited abnormalities of fibrinogen: 10-year clinical experience of an Italian group. Blood Coagul Fibrinolysis. 2006;17:235–40.PubMedCrossRef
Metadaten
Titel
Comparison of clinical phenotype with genetic and laboratory results in 31 patients with congenital dysfibrinogenemia in northern Slovakia
verfasst von
Tomas Simurda
Jana Zolkova
Zuzana Kolkova
Dusan Loderer
Miroslava Dobrotova
Ingrid Skornova
Monika Brunclíkova
Marian Grendar
Zora Lasabova
Jan Stasko
Peter Kubisz
Publikationsdatum
12.03.2020
Verlag
Springer Singapore
Erschienen in
International Journal of Hematology / Ausgabe 6/2020
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-020-02842-9

Weitere Artikel der Ausgabe 6/2020

International Journal of Hematology 6/2020 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.